Clinical Trial

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-09; most recent amendment 2024-09-04.
Status change: Not Yet Recruiting → Recruiting 2024-09-04
Trial Details
NCT Number NCT06493760
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Metastatic Colorectal Cancer
Enrollment 130 participants
Start Date 2024-09-03
Primary Completion 2025-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-09-19